The urgent need for improved vaccines in the Chinese market was made clear in recent weeks as the Chinese media reported the tragic news of several babies that died after they received hepatitis B vaccines made by a local manufacturer. There are big opportunities for the developers of improved safe...
Read more
Blog
Dynamix Partners with Teva Spinoff
Teva spinoff CleveXel Pharma is partnering with small molecule-focused Israeli firm Dynamix Pharmaceuticals to develop a dual-mechanism SYK/JAK molecule, DNX-04042, in rheumatoid arthritis (RA). The product, which is orally active, is Dynamix’ lead development program. Through this collaboration, the companies hope to bring the RA project to The thinking a...
Read more
BioLine RX Celiac Trial
BioLineRx (NASDAQ: BLRX; TASE: BLRX) has enrolled the first patient in a Phase 1/2 trial of BL-7010, for the treatment of celiac disease. The first patient was enrolled at Tampere Hospital in Finland. The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010...
Read more
Kadimastem Gets NIS 8.5 M for Stem Cells
Kadimastem (TASE:KDST), a developer of human pluripotent stem cell-based drug screening and therapeutic solutions, has received approval for a budget from the OCS for two development plans totaling NIS 8.5 million, for the development of cell therapy and drug screening solutions for diabetes, as well as for the development of...
Read more
Pluristem Deal With S. Korea
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) has issued to South Korea-based CHA Bio&Diostech (Kosdaq:CHA) shares of its common stock at a price of $4.16 per Pluristem common share, a premium of 26% over the closing price on December 16, 2013. The shares are subject to a lock up period...
Read more